Lunai Bioworks Announces 1-for-8 Reverse Stock Split Effective May 22 to Avoid Nasdaq Delisting
LNAI sits 68% above its 52-week low of $0.151.
Summary
Lunai Bioworks Inc. has announced a 1-for-8 reverse stock split, effective May 22, 2026, reducing its outstanding shares from approximately 36.27 million to 4.53 million. This move is a direct response to the company's recent Nasdaq delisting notice for failing to meet the minimum bid price requirement. While shareholders approved a reverse split within a specified range on May 13, 2026, this announcement provides the definitive ratio and effective date, which are crucial details for market participants. The company previously reported a Q3 net loss and issued a going concern warning, highlighting its precarious financial position. Traders will closely watch if this reverse split successfully enables Lunai Bioworks to regain and maintain Nasdaq compliance, and if it can address its fundamental operational and financial challenges.
At the time of this announcement, LNAI was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.15 to $4.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.